AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-79077783/dendreon-acquires-rights-key.html" title="Facts and information about Dendreon Acquires Rights To Key Cancer Antigens From Bayer.(CEA and MN antigens)">Dendreon Acquires Rights To Key Cancer Antigens From Bayer.(CEA and MN antigens)</a>
Close
Set up an RSS feed that alerts you when new articles from Vaccine Weekly are available.
Frequently asked questions about RSS feeds
Dendreon Acquires Rights To Key Cancer Antigens From Bayer.(CEA and MN antigens)
2001 OCT 17 - (NewsRx.com & NewsRx.net) -- Dendreon Corp. (DNDN) today announced it has entered into agreements with Bayer, Tarrytown, New York, to license two prominent tumor antigens for use in Dendreon's therapeutic cancer vaccines.
The first is a well-known antigen, carcinoembryonic antigen (CEA), which is commonly expressed by a wide range of cancers, including virtually all cases of colon cancer, 70% of lung cancers and approximately 65% of breast cancers. The second antigen, known as the "MN'' antigen, is prominent in cervical cancers and present in nearly 100% of kidney cancers and nearly 80% of colon cancers. ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- NEXELL LICENSES CANCER ANTIGENS FROM EPIMMUNE FOR CELL VACCINES.
- Magazine article from: BIOWORLD Today Willett, Matthew March 30, 2001 700+ words
...epitope package, a set of cancer antigens Nexell plans to use...to another group of cancer antigens. Further financial...is expected to enter Phase I/II studies next...is expected to enter Phase I/II trials a year...
- ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate...
- Press release article from: PR Newswire July 14, 2009 700+ words
...has entered into an agreement to exclusively license seven cancer antigens from Immunotope Inc., an antigen discovery company. These...next six months the company will fast-track DPX-0907 into Phase 1 clinical trials. "Advanced-stage breast, ovarian and...
- Dendreon Acquires Rights to Key Cancer Antigens From Bayer; New Targets Expand...
- Press release article from: Business Wire September 26, 2001 700+ words
...candidates, including APC8024, which is in Phase I clinical trials for breast, ovarian...the treatment of prostate cancer, in Phase III trials; Mylovenge(TM), for the treatment of multiple myeloma, in Phase II trials; and APC8024, currently...
- CORIXA, ZAMBON SIGN $21.5M DEAL FOCUSED ON CANCER ANTIGENS.
- Magazine article from: BIOWORLD Today Strickland, Debbie May 25, 1999 700+ words
...the right one." Corixa already has two cancer vaccines in Phase I clinical testing - a Her2/neu vaccine for late-stage breast...disease realm, Corixa last month reported positive interim Phase I trial results for a therapeutic vaccine utilizing its vaccine...
- Immunex Licenses Prostate Cancer Antigens From UroCor for Research Against...
- Press release article from: PR Newswire July 5, 2000 700+ words
Licensing Agreement Focuses on Antibody Research and Development SEATTLE and OKLAHOMA CITY, July 5 /PRNewswire/ -- In a move to develop monoclonal antibodies directed against prostate cancer, Immunex Corporation (Nasdaq: IMNX) has licensed rights to cancer-derived antigens from UroCor, Inc.
- NEWCO NEWS MABCURE'S REVAMPED HYBRIDOMA APPROACH SEEKS CANCER ANTIGENS.
- Magazine article from: BIOWORLD Today Boggs, Jennifer June 4, 2009 700+ words
Byline: Jennifer Boggs, Assistant Managing Editor With a new take on a classic drug discovery technology, 2008 start-up MabCure Inc. is on a mission to improve cancer treatment by developing monoclonal antibodies against difficult-to-pinpoint tumor-specific antigens for the diagnostics market. "If
- Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal...
- Press release article from: PR Newswire January 29, 2008 700+ words
...undergoing a global pivotal Phase 3 trial (the 'TARGET' trial...efficacy data for our pivotal Phase 3 TARGET trial of Proxinium...frequently over-expressed cancer antigens known. A growing body of evidence...drug is in a global pivotal Phase 3 clinical trial (the 'TARGET...
- ViRexx Announces Enrollment Completion of Ovarex'R' MAb Phase III Trial for...
- Press release article from: Business Wire December 14, 2005 700+ words
...enrollment in the first of two Phase III trials is a major milestone...Therapeutics. Two identical Phase III double-blind placebo...system to recognize specific "cancer" antigens as "foreign", triggering...currently the subject of two Phase III clinical trials being funded...